BASINGSTOKE, England, January 17 /PRNewswire/ --

- Non-Calcium Phosphate Binder for the Management of Hyperphosphataemia Now Available in 24 Countries

- NOT FOR DISTRIBUTION IN THE UNITED STATES

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announces that with the launch today in Spain of FOSRENOL (lanthanum carbonate), a non-calcium phosphate binder, Shire is celebrating the completion of the launch roll-out in the major European markets. FOSRENOL is the first of the company's medicines developed in-house from research molecule to market.

WEVELGEM, Belgium, January 17 /PRNewswire/ --

- With Photo

The Slim Form Patch, a diet patch containing algae extracts, has beaten the more traditional slimming methods in the slimming test on TV channel CBS. The patch technology has now reached the slimming industry. During the test one man lost 11.4 kg in four weeks. If you go to http://www.slimformpatch.eu you can see how the Slim Form Patch won the competition.

PHILADELPHIA and LONDON, January 17 /PRNewswire/ --

- Leading Research University is First in China to Purchase 100 Years of Web Of Science Comprehensive Backfile and Cited Reference Data

Thomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, today announced that Century of Science(TM) has been purchased by Peking University in China. Century of Science expands Web of Science with the most important scientific bibliographic and cited reference data covering the period from 1900 to 1944.

CARLSBAD, California, January 17 /PRNewswire/ --

Ablation Frontiers, Inc., a privately-held medical device company, announced today a successful series of catheter ablations using the company's Tip-Versatile Ablation Catheter(TM) (T-VAC). Dr. Vince Paul of the St. Peter's Hospital in Chertsey, United Kingdom is one of three leading European sites that have been evaluating this new multi-electrode linear ablation catheter since November 2007. He performed four ablation procedures for atrial flutter, a potentially dangerous irregular heart rhythm.

MAIDENHEAD, England, January 17 /PRNewswire/ -- Wyeth (WYE) today announced data from a Phase 3 study which showed that Enbrel significantly reduces the symptoms and signs of plaque psoriasis in children and adolescents with the disease.(1) This study was published in the January 17, 2008, issue of The New England Journal of Medicine.

The trial - the first time any biological treatment has been tested in children and adolescents with plaque psoriasis - showed 57% of patients on etanercept for 12 weeks achieved the 'gold-standard' in improvement compared to 11% of patients who received the placebo.(1) An application for use of Enbrel in managing psoriasis in children and adolescents has been submitted by Wyeth to the European Medicines Authority and is under review.

GAITHERSBURG, Maryland, January 16 /PRNewswire/ --

- With 2008 underway, Patton enters 25th year of communications equipment manufacturing

Patton Electronics -- the leader in business and carrier-class network access, connectivity, and Voice-over-IP equipment -- has entered their 25th year of designing, manufacturing, and marketing datacom and telecom equipment.

Having incorporated on 1 January 1984, Patton will mark their silver anniversary on 1 January 2009.